spacer
home > pmps > winter 2019 > the heart of healthcare
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Heart of Healthcare

Over the last decade, many pharmaceutical companies have moved from mass market drug development to investing in niche speciality medicines. This shift in the pharma industry has been driven by the recognition that the sector’s traditional blockbuster model had become unsustainable.

This is good news for patients with rare diseases. The rise of speciality treatments for chronic, complex, and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients.

According to IQVIA (formerly Quintiles and IMS Health), speciality medicines have enjoyed a decade of continued growth, which has put them on course to overtake the value of spending on traditional drugs in many of the world’s biggest pharma markets by 2022.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Chapper is the CEO at CHAPPER healthcare. He joined CHAPPER healthcare in 2013 from a successful career in law, where he worked at leading city law firms, as well as in an investment bank. Jonathan brought with him a wealth of commercial and legal experience, which he now applies to the pharma industry. CHAPPER healthcare is a leading specialist wholesaler and distributor and supplies pharmaceuticals to over 60 countries worldwide.
spacer
Jonathan Chapper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Realising the potential of single-use technology – As published in Manufacturing Chemist

In this article Zenith Technologies’ Global Director of Managed Services David Staunton and Scott Ripley, Global Marketing Director at GE Healthcare, discuss the benefits and patient impact of single-use technology with Manufacturing Chemist.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>

 
Industry Events

PHARM Connect Congress 2019

12-13 March 2019, Budapest Congress Center, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialisation in Central and Eastern Europe. The organiser - TEG The Events Group - cordially welcome all lead business professionals, academicians, researchers and peers from the field of pharmaceutical manufacturing and biotechnology to participate in the upcoming Congress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement